{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T21:04:09Z","timestamp":1792184649134,"version":"4.4.0"},"reference-count":21,"publisher":"Royal College of Psychiatrists","issue":"3","license":[{"start":{"date-parts":[[2018,1,2]],"date-time":"2018-01-02T00:00:00Z","timestamp":1514851200000},"content-version":"unspecified","delay-in-days":4690,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Psychiatry"],"published-print":{"date-parts":[[2005,3]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Selective serotonin reuptake inhibitors are effective in the treatment of social anxiety disorder and are currently regarded as the pharmacotherapy of choice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims<\/jats:title><jats:p>To investigate the efficacy and tolerability of escitalopram in the treatment of generalised social anxiety disorder.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>Patients with generalised social anxiety disorder were randomised to receive placebo (<jats:italic>n<\/jats:italic>=177) or 10\u201320 mg escitalopram (<jats:italic>n<\/jats:italic>=181) in a 12-week, double-blind trial. The primary outcome measure was the mean change from baseline to last assessment in the Liebowitz Social Anxiety Scale (LSAS) total score.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The study showed a statistically superior therapeutic effect for escitalopram compared with placebo on the LSAS total score (P=0.005). There were significantly more responders to treatment for escitalopram than for placebo (54% v. 39%; P &lt; 0.0 1). The clinical relevance of these findings was supported by significant reduction in the work and social components of the Sheehan Disability Scale and by the good tolerability of escitalopram treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Escitalopram was efficacious and well tolerated in the treatment of generalised social anxiety disorder.<\/jats:p><\/jats:sec>","DOI":"10.1192\/bjp.186.3.222","type":"journal-article","created":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:15:03Z","timestamp":1109636103000},"page":"222-226","source":"Crossref","is-referenced-by-count":110,"title":["Escitalopram in the treatment of social anxiety disorder"],"prefix":"10.1192","volume":"186","author":[{"given":"Siegfried","family":"Kasper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan J.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Loft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rico","family":"Nil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"170","published-online":{"date-parts":[[2018,1,2]]},"reference":[{"key":"S0007125000078545_ref5","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"S0007125000078545_ref2","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"1994"},{"key":"S0007125000078545_ref20","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200205000-00001"},{"key":"S0007125000078545_ref1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1999.tb10845.x"},{"key":"S0007125000078545_ref3","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.175.2.120"},{"key":"S0007125000078545_ref4","first-page":"54","article-title":"Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety","volume":"59","author":"Ballenger","year":"1998","journal-title":"Journal of Clinical Psychiatry"},{"key":"S0007125000078545_ref12","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.134.4.382"},{"key":"S0007125000078545_ref18","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.2.275"},{"key":"S0007125000078545_ref14","volume-title":"The Anxiety Disease","author":"Sheehan","year":"1983"},{"key":"S0007125000078545_ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(98)00094-9"},{"key":"S0007125000078545_ref7","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199606003-00007"},{"key":"S0007125000078545_ref8","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1520-6394(2000)11:3<87::AID-DA1>3.0.CO;2-9"},{"key":"S0007125000078545_ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(98)00093-7"},{"key":"S0007125000078545_ref13","doi-asserted-by":"publisher","DOI":"10.1177\/026988110101500314"},{"key":"S0007125000078545_ref15","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic interview for DSM \u2013IV and ICD \u2013 10","volume":"59","author":"Sheehan","year":"1998","journal-title":"Journal of Clinical Psychiatry"},{"key":"S0007125000078545_ref16","first-page":"707","article-title":"Paroxetine treatment of generalised social phobia (social anxiety disorder) \u2013 a randomised controlled trial","volume":"26","author":"Stein","year":"1998","journal-title":"JAMA"},{"key":"S0007125000078545_ref17","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1176\/ajp.156.5.756","article-title":"Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study","volume":"156","author":"Stein","year":"1999","journal-title":"American Journal of Psychiatry"},{"key":"S0007125000078545_ref19","doi-asserted-by":"publisher","DOI":"10.3109\/15622970009150563"},{"key":"S0007125000078545_ref21","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291798008174"},{"key":"S0007125000078545_ref10","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v63n0113"},{"key":"S0007125000078545_ref9","doi-asserted-by":"publisher","DOI":"10.1159\/000414022"}],"container-title":["British Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0007125000078545","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T22:23:41Z","timestamp":1706048621000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0007125000078545\/type\/journal_article"}},"subtitle":["Randomised, placebo-controlled, flexible-dosage study"],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["S0007125000078545"],"URL":"https:\/\/doi.org\/10.1192\/bjp.186.3.222","relation":{},"ISSN":["0007-1250","1472-1465"],"issn-type":[{"value":"0007-1250","type":"print"},{"value":"1472-1465","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,3]]}}}